May 2018—Sebia launched two CE-marked serum free light chain assays, Sebia FLC Kappa and Sebia FLC Lambda, for multiple myeloma testing. The two assays aim to provide more consistent results by overcoming the challenges in analytical performance and coherence encountered in current testing methods. The assays are based on ELISA technology and have been developed to make the monitoring of multiple myeloma patients simpler and easier for health care professionals. The company will apply for FDA 510(k) clearance later this year.
Sebia, +33 1 69 89 80 80